Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.77 | 4.51% | 0.03 |
Earnings due: May 10
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | 4.51% | |
| Stochastic Reached Oversold | Weakness | 4.51% | |
| Wide Bands | Range Expansion | 4.51% | |
| Down 3 Days in a Row | Weakness | 4.51% | |
| Oversold Stochastic | Weakness | 4.51% | |
| 200 DMA Resistance | Bearish | 1.71% |
| Alert | Time |
|---|---|
| 50 DMA Resistance | about 8 hours ago |
| 10 DMA Resistance | about 8 hours ago |
| Rose Above 50 DMA | about 9 hours ago |
| Rose Above 10 DMA | about 9 hours ago |
| Up 5% | about 9 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/10/2024
Citius Pharmaceuticals, Inc. Description
Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Drugs Inflammation Catheter Antibiotics Cancer Care Care Products Prescription Product Prescription Products Acetamides Bloodstream Infections Lidocaine
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.56 |
| 52 Week Low | 0.6 |
| Average Volume | 885,891 |
| 200-Day Moving Average | 0.81 |
| 50-Day Moving Average | 0.79 |
| 20-Day Moving Average | 0.86 |
| 10-Day Moving Average | 0.79 |
| Average True Range | 0.09 |
| RSI (14) | 44.75 |
| ADX | 24.27 |
| +DI | 32.46 |
| -DI | 21.64 |
| Chandelier Exit (Long, 3 ATRs) | 0.81 |
| Chandelier Exit (Short, 3 ATRs) | 0.96 |
| Upper Bollinger Bands | 1.04 |
| Lower Bollinger Band | 0.68 |
| Percent B (%b) | 0.25 |
| BandWidth | 42.41 |
| MACD Line | -0.01 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.0194 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.87 | ||||
| Resistance 3 (R3) | 0.87 | 0.83 | 0.85 | ||
| Resistance 2 (R2) | 0.83 | 0.81 | 0.83 | 0.85 | |
| Resistance 1 (R1) | 0.80 | 0.79 | 0.82 | 0.80 | 0.84 |
| Pivot Point | 0.77 | 0.77 | 0.77 | 0.77 | 0.77 |
| Support 1 (S1) | 0.73 | 0.74 | 0.75 | 0.73 | 0.69 |
| Support 2 (S2) | 0.70 | 0.72 | 0.70 | 0.69 | |
| Support 3 (S3) | 0.66 | 0.70 | 0.68 | ||
| Support 4 (S4) | 0.66 |
